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DOI 10.1016/j.stem.2008.03.007In the 10 years that the technology to
produce human embryonic stem cell lines
has been available, hundreds of lines have
been derived in numerous global loca-
tions. These cell lines are being used
by researchers across diverse scientific
fields to investigate the basic biology, clin-
ical potential, and pharmaceutical appli-
cations of these cells and their progeny.
In this fast-moving and rapidly growing
field, how can we ensure that data ge-
nerated by different laboratories using
the same cell lines are comparable, re-
producible, and consistent? One sugges-
tion would be to ensure the quality of the
‘‘seed stock’’ material received and used
by researchers. Because a number of
laboratories worldwide provide stem cell
lines to the scientific community, it seems
logical to explore the harmonization of
practices between distributors to estab-
lish cohesive standards and aid the global
movement of stem cell lines to the re-
search community. In the future, when
these cells arrive in the clinic for therapeu-
tic use, this consensus of ‘‘best practice’’
should ensure the consistency and facili-
tate the dissemination of these valuable
materials.
In early 2007, the International Stem
Cell Forum (ISCF) met to discuss these
concerns and recommended the funding
of an initiative to bring together distribu-
tors of stem cell lines throughout the
world. The ISCF is a consortium of 21
international and national funding bodies
allied to stem cell research (The Interna-
tional Stem Cell Initiative, 2007). This ini-
tiative, the International Cell Banking Ini-
tiative (ICBI), held its inaugural meeting
at the Jackson Laboratory (Bar Harbor,
ME, USA) October 18–19, 2007 and was
coordinated by Dr. Glyn Stacey (National
Institute for Biological Standards and
Control, UK). The aim of the meeting was
to engage the global distribution centers
in discussion on best practice and fromthis discussion produce a consensus
guidance document for stem cell banks.
The meeting attracted delegates from 17
countries representing national stem cell
banks, culture collections, research labs,
funding bodies, advisory bodies, and
other interested, international bodies. Be-
cause this initiative was set up to facilitate
the dissemination of standards through-
out the community of stem cell providers,
it was fitting that the first session was
dedicated to exploring the worldwide ac-
tivity of the banking groups represented.
Eighteen talks were presented by groups
from Asia, Australia, Europe, and North
America. The presentations made obvi-
ous the diversity in size, function, and
performance of the banks represented
and the impact this diversity must have
on the local practices for each bank. The
ICBI encompassed both small and large
public and private banks with collections
ranging from 3 to more than 60 lines.
Some banks were still at the theoretical
stage, whereas others were fully opera-
tional. Collections varied widely across
banks, and differences were evident in lin-
eages, derivation methods, and cell types
within each bank. Most importantly, it be-
came apparent that the national regula-
tory frameworks and ethical provenance
for each group differed, and these frame-
works needed to be considered and
respected when cells were being trans-
ferred. Despite all of these apparent differ-
ences, participants were encouraged to
find commonality that could enable the
unification of principles and practices.
Following the reports from the banks,
the ICBI outlined the theoretical principles
in the process of cell banking and distri-
bution. In order to obtain a consensus
for best practice, however, it was impera-
tive that essential terms be defined, ac-
cepted, and used by all embryonic stem
cell line providers (Lomax and McNab,
2008). Even a term as fundamental asCell Stem‘‘bank’’ needed a definition. It was there-
fore decided that a working group be es-
tablished to look at terminologies relevant
to the banking process and provide defi-
nitions for use by the ICBI.
Themainpractices involved in thebank-
ing process were outlined in principle for
discussion by the ICBI: standard operat-
ing procedures (SOP), archiving and doc-
umenting deposited material for refer-
ence, preparation of premaster, master,
and distribution banks, size of banks, off-
site storage, characterization, cryopreser-
vation, testing regimes, release criteria,
material transfer agreements (MTA), prod-
uct sheets, and transportation. In-depth
discussion followed on the practical pro-
cesses, systems, and methodologies al-
ready employed by the different banks.
The conversation centered on three
fundamental questions. (1) How can we
ensure that all cell providers send out
a good quality product with a common
specification? (2) What sort and extent of
testing is considered acceptable? (3)
How could current methods be improved,
standardized, and shared?
When discussing potential testing re-
quirements, safety issues related to the
cell lines were considered of paramount
importance, both from the perspective
of the banks shipping the cells and the
requestor receiving the cells. It was rec-
ognized, however, that due to escalating
costs, an assessment of risk and cost to
benefit needed to be considered when
establishing a pathogen-testing program.
In addition, it was noted that cells should
have a minimum amount of identity and
characterization data available to the re-
questor. Panels of appropriate markers
have been provided by a number of regu-
latory agencies worldwide, and these
should be consulted. Stability of the cells,
both genetically and functionally, during
their expansion and banking needed to
be examined and should be tested withCell 2, April 2008 ª2008 Elsevier Inc. 305
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pluripotency assays. To promote consen-
sus on specific testing requirements, sev-
eral specialized working groups were
established, including those focused
on setting specifications for embryonic
stem cell lines, karyotyping, and myco-
plasma detection. The need for criteria
for identification and characterization of
stem cells based on genetic identity test-
ing, morphology, and the use of a com-
mon set of phenotypic canonical markers
were key areas of consensus. Partici-
pants agreed testing should ensure that
cells being shipped are free from contam-
ination, genetically authentic, viable, sta-
ble, and pluripotent.
To assure quality, the need for good,
complete documentation and auditing
was emphasized as an essential require-
ment for stem cell banking. This would
enable traceability for each cell line de-
posited in a given bank from consent
through to distribution. It would also en-306 Cell Stem Cell 2, April 2008 ª2008 Elsevable the production of a certificate of
analysis that would accompany any ship-
ments of corresponding cells. The neces-
sity for training requestors in embryonic
stem cell culture techniques and the
provision of technical support to the re-
questors, postdispatch of the cell lines,
was considered an essential duty of the
cell line distributors.
The main purpose of this meeting was
to look toward a consensus of practices
that would accommodate all of the banks
present and facilitate the global move-
ment of cells, yet not be over prescriptive
and onerous. Overall, the 2 day meeting
resulted in a greater appreciation of the
diversity and commonality of practices
among cell distribution groups around
the world. It was clear that development
of guidelines would ensure harmonization
among the global providers of human
embryonic stem cell lines; however, the
discussions highlighted many issues that
needed to be explored and resolved (forier Inc.a regulatory perspective, see O’Rourke
et al. [2008] in this issue). The overarching
ethical considerations were recognized
as an area of obvious discourse, and a
better understanding was implicit to
any consensus guidance documentation
involving the use of human embryonic
stem cells. The ethical and legal equiva-
lency among banks, their depositors,
and requestors also needed to be consid-
ered on a global level. As a result of this
meeting, guidelines are being prepared
that will detail the consensus of the Initia-
tive. This document is expected to be
submitted for publication in April of 2008.
REFERENCES
The International Stem Cell Initiative (2007). Nat.
Biotechnol. 25, 803–816.
Lomax, G., and McNab, A. (2008). Cell Stem Cell
2, 201–202.
O’Rourke, P.P., Abelman, M., and Heffernan, K.G.
(2008). Cell Stem Cell 2, this issue, 307–312.
